HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor.

Abstract
Many neurodegenerative diseases, including tauopathies, Parkinson's disease, amyotrophic lateral sclerosis, and the polyglutamine diseases, are characterized by intracellular aggregation of pathogenic proteins. It is difficult to study modifiers of this process in intact cells in a high-throughput and quantitative manner, although this could facilitate molecular insights into disease pathogenesis. Here we introduce a high-throughput assay to measure intracellular polyglutamine protein aggregation using fluorescence resonance energy transfer (FRET). We screened over 2800 biologically active small molecules for inhibitory activity and have characterized one lead compound in detail. Y-27632, an inhibitor of the Rho-associated kinase p160ROCK, diminished polyglutamine protein aggregation (EC(50) congruent with 5 microM) and reduced neurodegeneration in a Drosophila model of polyglutamine disease. This establishes a novel high-throughput approach to study protein misfolding and aggregation associated with neurodegenerative diseases and implicates a signaling pathway of previously unrecognized importance in polyglutamine protein processing.
AuthorsSonia K Pollitt, Judit Pallos, Jieya Shao, Urvee A Desai, Aye Aye K Ma, Leslie Michels Thompson, J Lawrence Marsh, Marc I Diamond
JournalNeuron (Neuron) Vol. 40 Issue 4 Pg. 685-94 (Nov 13 2003) ISSN: 0896-6273 [Print] United States
PMID14622574 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Amides
  • Enzyme Inhibitors
  • HTT protein, human
  • Huntingtin Protein
  • Intracellular Signaling Peptides and Proteins
  • Nerve Tissue Proteins
  • Nuclear Proteins
  • Peptides
  • Pyridines
  • Y 27632
  • polyglutamine
  • Protein Serine-Threonine Kinases
  • rho-Associated Kinases
Topics
  • Amides (pharmacology, therapeutic use)
  • Animals
  • Animals, Genetically Modified
  • Biological Assay (methods)
  • COS Cells
  • Cell Death (drug effects, genetics)
  • Disease Models, Animal
  • Down-Regulation (drug effects, genetics)
  • Drosophila melanogaster
  • Drug Evaluation, Preclinical (methods)
  • Enzyme Inhibitors (pharmacology, therapeutic use)
  • Fluorescence Resonance Energy Transfer (methods)
  • Humans
  • Huntingtin Protein
  • Inclusion Bodies (chemistry, drug effects, metabolism)
  • Intracellular Signaling Peptides and Proteins
  • Nerve Tissue Proteins (deficiency, genetics)
  • Neurodegenerative Diseases (drug therapy, genetics, metabolism)
  • Nuclear Proteins (deficiency, genetics)
  • Peptides (analysis, antagonists & inhibitors, metabolism)
  • Photoreceptor Cells, Invertebrate (drug effects, metabolism, pathology)
  • Protein Folding
  • Protein Serine-Threonine Kinases (antagonists & inhibitors, metabolism)
  • Pyridines (pharmacology, therapeutic use)
  • Signal Transduction (drug effects, genetics)
  • Trinucleotide Repeat Expansion (drug effects, genetics)
  • rho-Associated Kinases

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: